Anti–IL-5 (mepolizumab) therapy reduces eosinophil activation ex vivo and increases IL-5 and IL-5 receptor levels
- 1 June 2008
- journal article
- Published by Elsevier in Journal of Allergy and Clinical Immunology
- Vol. 121 (6) , 1473-1483.e4
- https://doi.org/10.1016/j.jaci.2008.02.033
Abstract
No abstract availableKeywords
This publication has 39 references indexed in Scilit:
- Schistosoma mansoni infection in eosinophil lineage–ablated miceBlood, 2006
- Approaches to the treatment of hypereosinophilic syndromes: A workshop summary reportJournal of Allergy and Clinical Immunology, 2006
- THE EOSINOPHILAnnual Review of Immunology, 2006
- Safety and efficacy of the monoclonal anti–interleukin-5 antibody SCH55700 in the treatment of patients with hypereosinophilic syndromeBlood, 2004
- Anti–interleukin-5 (mepolizumab) therapy for hypereosinophilic syndromes☆Journal of Allergy and Clinical Immunology, 2004
- Eosinophilic gastrointestinal disorders (EGID)☆Journal of Allergy and Clinical Immunology, 2004
- Abnormal Clones of T Cells Producing Interleukin-5 in Idiopathic EosinophiliaNew England Journal of Medicine, 1999
- Interleukin 5 deficiency abolishes eosinophilia, airways hyperreactivity, and lung damage in a mouse asthma model.The Journal of Experimental Medicine, 1996
- Internalization, lysosomal degradation and new synthesis of surface membrane CD4 in phorbol ester-activated T-lymphocytes and U-937 cellsExperimental Cell Research, 1992
- Interleukin 5 and phenotypically altered eosinophils in the blood of patients with the idiopathic hypereosinophilic syndrome.The Journal of Experimental Medicine, 1989